Citations

Mayo Clinic

Showing 10 of 108147 citations.

Radiology: Cardiothoracic Imaging Highlights 2025
Sanchez, Daniel Alfonso Pinos , Farias, Lucas de Pádua Gomes de , Onnis, Carlotta , Escalon, Joanna G. , Hanneman, Kate , Litt, Harold , Gulsin, Gaurav S. , Pinos, Daniel , Gomes de Farias, Lucas de Pádua , Suchá, Dominika , Escalon, Joanna G , Hanneman, Kate , Abbara, Suhny , Litt, Harold I , Gulsin, Gaurav S , Suchá, Dominika , Mastrodicasa, Domenico

Radiology: Cardiothoracic Imaging | June 11, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1148/ryct.260065 | PMID 42274320 Get It

Articles published in Radiology: Cardiothoracic Imaging in 2025 highlight advances in cardiothoracic imaging through technical innovation, quantitative biomarkers, and artificial intelligence applications that support improved diagnosis, risk stratification, and patient-centered management across cardiac, vascular, and thoracic disease.
Climate stressors and impact on cardio-oncology burden in the united states: nationwide and geographically matched analyses
Hassan, I, Kurasz, A, Aldalaeen, R, Alhammouri, H, Alasmar, R, Saif, R, Ibrahim, M, Alghzlawi, I, Shehab, M, Rafaat, K, Kuzma, L, Abohashem, S, Hassan, Ibrahim , Hassan, Ibrahim, Kurasz, Anna , Aldalaeen, Raneem, Al-Asmar, Rahmeh , SAIF, RIYADH, Alghzlawi, Ibrahim , Raafat, Kareem Wael , Kuzma, L, Abohashem, Shady

European Journal of Preventive Cardiology | June 11, 2026 | Volume: 33 | Issue: Supplement_2 | Pages: No page available

10.1093/eurjpc/zwag249.289 Get It

Abstract Background Climate-related stressors such as heat, wildfires, and extreme weather are increasingly recognized as determinants of cardiovascular and oncologic health. However, their joint impact on overlapping cancer–cardiovascular disease (CVD) burdens remains unknown. We developed a Cardio-Oncology Burden Index (COBI) to quantify the co-prevalence of cancer and CVD at the community level and examined its association with climate vulnerability across U.S. census tracts. Methods We conducted a cross-sectional ecological analysis of 82,679 census tracts (328,683,841 residents) using the CDC PLACES database. COBI was derived using principal component analysis of age-adjusted prevalence of cancer, coronary artery disease, and stroke. The Climate Burden Index (CBI, 0–1 percentile) integrates multiple climate-related exposures, including extreme temperature, wildfire frequency, and severe weather events. Population-weighted mixed-effects regression models with county-level random effects estimated associations between CBI and COBI, adjusting for region, rurality, and environmental justice indicators. β coefficients represent percentage-point differences in COBI per unit (or category) increase in climate burden. Exposure–response relationships were examined using restricted cubic splines (RCS). Robustness was assessed via geographically matched (<50 km) and fully matched (region, rural–urban commuting area, and environmental justice) analyses. Results Marked spatial heterogeneity was observed in both CBI and COBI across the U.S. (Fig. A–B). Higher climate burden was consistently associated with greater cardio-oncology burden (Fig. C), demonstrating a dose–response relationship: second vs lowest quartile β=0.92 (95% CI, 0.61–1.24); third vs lowest quartile β=1.61 (95% CI, 1.30–1.92); highest vs lowest quartile β=3.44 (95% CI, 3.11–3.76). The RCS model revealed a significant non-linear association (p_non-linear<0.001), with a plateau at moderate exposures and a steep rise at the highest CBI levels (Fig. D). Results remained robust in sensitivity analyses (β=4.17 [95% CI, 3.62–4.71] for geographically matched; β=4.39 [95% CI, 4.10–4.69] for fully matched tracts; Table). Conclusions Greater climate burden is independently associated with higher cardio-oncology burden across U.S. communities, with disproportionate effects in the most climate-vulnerable areas. This novel, population-level linkage between climate stress and onco-cardiovascular disease burden, highlights an emerging syndemic at the intersection of environment, cancer, and CVD. Targeted mitigation and prevention strategies integrating environmental resilience into chronic disease prevention are urgently needed.For image description, please refer to the figure legend and surrounding text.
Lipomatous atrial septum thickness and all-cause mortality across the LASH severity spectrum
Martinez-Dominguez, P, Nouraei, H, Wong, C Kit, Lara-Breitinger, K, Lopez-Jimenez, F, Bird, J G, Kane, G C, Pislaru, S V, Tsaban, G, Martinez‐Dominguez, Pavel , Nouraei, Hasti , Lara-Breitinger, Kyla M , López-Jiménez, Francisco , Kane, Garvan C. , Pislaru, S V, Tsaban, Gal

European Journal of Preventive Cardiology | June 11, 2026 | Volume: 33 | Issue: Supplement_2 | Pages: No page available

10.1093/eurjpc/zwag249.276 Get It

Abstract Background Lipomatous atrial septal hypertrophy (LASH) is generally viewed as a benign anatomical finding. Although extracardiac fat depots have been linked to adverse cardiometabolic outcomes, the prognostic implications of LASH have not been well defined. Purpose To evaluate whether LASH thickness is independently associated with long-term all-cause mortality. Methods We reviewed adult patients who underwent diagnostic transesophageal echocardiography at our Clinic sites from 2010–2017. LASH was identified by a dumbbell-shaped interatrial septum with maximal thickening ≥5 mm in the bicaval midesophageal view. All-cause mortality through January 1, 2024, served as the primary endpoint. Septal thickness was evaluated using restricted cubic splines and Cox proportional hazards models adjusted for age, sex, body mass index, Charlson Comorbidity Index, and left ventricular ejection fraction. Results Among 1,397 patients (mean age 69±12 years; 60% male), median LASH thickness was 14.2±4.4 mm. LASH severity was classified as mild (<15 mm; n=763), moderate (15-20 mm; n=522), or severe (>20 mm; n=112). During 7.5±4.0 years of follow-up, 586 deaths (42%) occurred. Mortality was higher with increasing septal thickness (37%, 46%, and 56%; p < 0.001). Each 1-mm increase in LASH-thickness was associated with higher adjusted mortality (adjusted-hazard-ratio 1.03; 95%-confidence-interval 1.01-1.05). Spline modeling suggested a risk increase beginning near 16 mm; thickness >16 mm carried a 26% higher mortality risk (adjusted-hazard-ratio 1.26; 95%-confidence-interval 1.06-1.50). Conclusions LASH was associated with long-term mortality independent of BMI and other clinical factors. Septal fat accumulation may provide a useful, noninvasive marker that complements broader cardiac risk assessment.Risk for all-cause mortality across LASHFor image description, please refer to the figure legend and surrounding text.
Association between sleep midpoint and body fat in patients enrolled in cardiac rehabilitation
Covassin, N, Maiti, D, Lopez-Jimenez, F, Mansukhani, M P, Aviles, L M Ortega, Somers, V K, Bonikowske, A R, Covassin, Naima , Maiti, Dolly, López-Jiménez, Francisco , Mansukhani, Meghna P. , Ortega-Aviles, L M , Somers, Virend K. , Bonikowske, Amanda R.

European Journal of Preventive Cardiology | June 11, 2026 | Volume: 33 | Issue: Supplement_2 | Pages: No page available

10.1093/eurjpc/zwag249.166 Get It

Abstract Background The implications of poor sleep for cardiovascular disease risk are increasingly recognised. Although previous research has focused on clinical sleep disorders, emerging evidence highlights the relevance of subclinical sleep aspects for cardiovascular health. Sleep midpoint, an index of sleep timing and a proxy of circadian phase, has been shown to be associated with markers of cardiometabolic risk, including obesity, in the general population. Purpose We aimed to assess whether sleep midpoint was related to body composition measures in patients with coronary heart disease enrolled in cardiac rehabilitation (CR). Methods Study participants were recruited from the patient population referred to our CR center for acute coronary syndrome or coronary revascularisation. Shift work was exclusionary. Participants underwent sleep testing prior to entering the CR program, including completion of one week of wrist actigraphy and sleep log. Using actigraphy-derived sleep metrics, sleep midpoint was calculated as the middle time (hh:mm) between bedtime and wake up time for each individual night, and averaged across the monitoring week. Based on the median sleep midpoint of the sample, participants were categorised as having early (before 2:42) or late (after 2:42) sleep midpoint. Body composition and regional fat distribution were determined by whole-body dual-energy absorptiometry (DEXA). Between-group characteristics were compared using independent t-test, Mann-Whitney U test and Chi-square statistics as appropriate. Linear regression was used to test the association between sleep midpoint and body fat measures. Results Thirty-one participants (26 males, 64.7±12.5 years) completed both actigraphy and DEXA assessments. Demographics, lifestyle, and clinical characteristics were similar between patients with early sleep midpoint (n=15; sleep midpoint, hh:mm: 2:00, range 0:57 to 2:41) and patients with late sleep midpoint (n=16; sleep midpoint 3:18, range 2:42 to 4:17). Despite comparable body mass index between groups (p=0.21), patients with late sleep midpoint had significantly higher total body fat percentage (p=0.017), android fat percentage (p=0.015), and gynoid fat percentage (p=0.045). Late sleep midpoint remained significantly associated with adiposity measures in age- and sex-adjusted analysis (total body fat percentage, beta = 0.371, 95% CI 0.063 to 0.68; android fat percentage, beta = 0.394, 95% CI 0.078 to 0.71; gynoid fat percentage, beta = 0.301, 95% CI 0.007 to 0.596). Conclusions Late sleep midpoint was associated with excess adiposity in patients with coronary heart disease enrolled in CR. These findings support the predictive value of sleep timing for cardiometabolic risk and emphasise the importance of objective sleep assessment for secondary prevention.
Pediatric epilepsy surgery: Global survey of invasive explorations
Ramantani, Georgia , Feucht, Martha , Cserpán, Dorottya , Aparicio, Javier , Arzimanoglou, Alexis , Bartoloméi, Fabrice , Bingaman, William , Braun, Kees P. J. , Burman, Richard J. , Cao, Dezhi , Caraballo, Roberto , Cloppenborg, Thomas , Cross, J. Helen , Cukiert, Cristine Mella , Curry, Daniel J. , Dimova, Petia , Eltze, Christin , Hallböök, T , Holthausen, Hans , Jayalakshmi, Sita , Jiang, Yuwu , Kannan, Lakshminarayanan , Lallas, Matt, Patil, Sandeep Bhagwan , Pérez‐Jiménez, María Ángeles, Pérez‐Poveda, Juan Carlos , Pieper, Tom , Rona, Sabine, Shetty, Jay , Smith, Mary Lou , Suwanpakdee, Piradee , Tarta‐Arsene, Oana , Tripathi, Manjari , Moosa, Ahsan N. , Weiner, Howard , Cai, Lixin , Sorbets, Sarah Ferrand , Group, ILAE Pediatric Epilepsy Surgery Taskforce and Study, Barba, Carmen , Chipaux-Raffo, Mathilde , Cloppenborg, Thomas , Cross, Helen J , Cukiert, Arthur , Curry, Daniel J , De Palma, Luca , Dimova, Petia , Eltze, Christin , Englot, Dario J , Nico Enslin, Johannes M , Fallah, Aria , Francione, Stefano , Gill, Deepak , Harvey, A Simon , Holthausen, Hans , Jayalakshmi, Sita , Jiang, Yuwu , Kannan, Lakshminarayanan , Lallas, Matt , Patil, Sandeep Bhagwan , Pérez-Poveda, Juan Carlos , San Antonio-Arce, Victoria , Shetty, Jay , Smith, Mary Lou , Suwanpakdee, Piradee , Tarta Arsene, Oana , Tassi, Laura , Tisdall, Martin M , Tripathi, Manjari , Valappil, Ahsan Moosa Naduvil , Wirrell, Elaine C , Cai, Li-Xin , Ferrand Sorbets, Sarah , Wilmshurst, Jo M , Ramantani, Georgia , Feucht, Martha , Burman, Richard J , Englot, Dario J. , Enslin, Nico , Fallah, Aria , Gill, Deepak , Pérez-Jiménez, María Ángeles, Tisdall, Martin , Wirrell, Elaine , Group, ILAE Pediatric Epilepsy Surgery Task Force and Study, Barba, Carmen

Epilepsia | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70325 | PMID 42274288 Get It

Abstract Objective Invasive presurgical evaluation plays a key role in pediatric epilepsy surgery, particularly in magnetic resonance imaging (MRI)‐negative cases, by guiding resective, disconnective, or ablative procedures. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Taskforce study provides an updated global overview of current invasive evaluation practices. Methods Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) in 29 countries across six continents. Included were children and adolescents who underwent presurgical evaluation and epilepsy surgery in 2023. The study was designed to enable comparison with the similar ILAE survey conducted in 2004. Results A total of 2427 patients were included. Invasive evaluations were performed in 21.1% of cases, most frequently in North America (33.7%, higher than Europe: 18.0%, p = .003). Among invasive cases, 32.3% had no detectable MRI abnormalities. The main indication for invasive evaluation was seizure onset localization (88.1%), followed by motor or sensory mapping (17.2%) and language mapping (14.2%). Stereoelectroencephalography (SEEG) was the predominant technique (19.8% overall, 93.6% of invasive cases), more common in North America (30.0%, p = .021) and less common in South America (7.4%, p < .001). Subdural electrodes were used in only 3.2% of invasive cases, and combined depth and subdural approaches in 3.2%. SEEG‐guided radiofrequency thermocoagulation (RF‐TC) was performed in 40.9% of SEEG cases, most commonly in Asia (63.8%). In 16.2% of invasive evaluations, patients did not proceed to resection, disconnection, or ablation, with the highest rate in Europe (28.5%). Significance This global survey provides the first broad overview of invasive evaluation practices in pediatric epilepsy surgery across participating centers worldwide. It highlights the widespread adoption of SEEG, declining use of subdural electrodes, and increasing application of SEEG‐guided RF‐TC. The high proportion of MRI‐negative cases and the considerable proportion of patients not proceeding to resection, disconnection, or ablation underscore the complexity of contemporary surgical candidates and the need for further refinement of selection strategies.
Toward the Future: A Race‐Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug Dosing
Scheetz, Marc H. , Lodise, Thomas P. , Rhodes, Nathaniel J. , Pai, Manjunath P. , Frazee, Erin N. , Neely, Michael , Frazee, Erin N , Neely, Michael N , Scheetz, Marc H , Rhodes, Nathaniel J , Lodise, Thomas P.

Clinical Pharmacology & Therapeutics | June 11, 2026 | Volume: 120 | Issue: 3 | Pages: 639-647

10.1002/cpt.70358 | PMID 42274272 Get It

Accurate assessment of renal function is fundamental to dosing renally eliminated drugs. For decades, serum creatinine–based estimating equations have been used to approximate glomerular filtration rate (GFR) for this purpose. While these equations perform reasonably well at the population level, they exhibit substantial individual‐level imprecision and inaccuracy. Simultaneously, recent efforts to remove race from estimating equations addressed important ethical concerns but did not resolve the core limitation of population‐based estimation for individual drug dosing. In this perspective, we argue that personalized dosing requires a shift away from demographic surrogates toward direct measurement of renal clearance and clarify when incremental therapeutic complexity is warranted. We review the limitations of endogenous biomarkers, discuss the role of cystatin C, and propose exogenously measured GFR using iohexol integrated within a Bayesian pharmacometric framework as a clinically actionable approach to individualized drug dosing. Practically, this framework can be implemented by administering a small iohexol dose, collecting sparse timed samples, estimating absolute mGFR and its uncertainty with Bayesian software, and using that posterior estimate to refine renal dose selection.
Correction: Artificial Intelligence in Clinical Gastroenterology: Promise, Pace, and Proof
Stidham, Ryan W. , Stidham, Ryan W

American Journal of Gastroenterology | June 11, 2026 | Volume: 121 | Issue: 7 | Pages: 1788-1788

10.14309/ajg.0000000000004046 | PMID 42274134 Get It

Brent A. Reynolds, pioneer of adult neural stem cell biology
Deleyrolle, Loic P.

Stem Cells | June 11, 2026 | Volume: 44 | Issue: 8 | Pages: No page available

10.1093/stmcls/sxag036 | PMID 42281283 Get It

Reversed sequence radiation therapy for treatment of primary central nervous system choriocarcinoma prioritizing for bleeding control: A case report
Zhou, Anita , Carmicheal, Joseph , Shonka, Nicole A., Zhang, Chi, Zhou, Anita

Sage Open Medical Case Reports | June 11, 2026 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/2050313x261426770 | PMID 42292891 Get It

Primary central nervous system choriocarcinoma is a non-germinomatous germ cell tumor with a highly malignant character, comprising up to 5% of all central nervous system germ cell tumors. Locations affected can include suprasellar or pineal locations most commonly, with others including the basal ganglia and lateral ventricles. Guidelines do not specify an optimal radiation regimen but recommend proceeding with maximally safe resection if feasible and then chemotherapy before radiotherapy. Radiation is often comprised of craniospinal irradiation with subsequent tumor bed boost. We present a case of an adult male with a primary central nervous system choriocarcinoma who underwent reversed sequence radiation therapy with photon tumor bed boost before proton craniospinal irradiation due to recurrent intracranial hemorrhages with long-term control of cancer and no subsequent hemorrhages. This case highlights the excellent outcome and feasibility of reversed sequence radiotherapy on choriocarcinoma in hemorrhage and tumor control.
Remote, self‐administered, smartphone cognitive testing in a registry‐based cohort: Feasibility, reliability, and validity findings
Dhanam, Sreya , Taylor, Jack C. , Fregly, Ray, Kwang, Winnie, Wise, Amy B. , Heuer, Hilary W. , Forsberg, Leah K. , Kramer, Joel H. , Rosen, Howard J., Mackin, R. Scott , Weiner, Michael W., Nosheny, Rachel L. , Boxer, Adam L., Staffaroni, Adam M. , Registry, and the Brain Health, Staffaroni, Adam M , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Maruff, Paul , Boeve, Bradley F. , Boxer, Adam L. , Registry, and the Brain Health

Alzheimer's & Dementia | June 11, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71580 | PMID 42273832 Get It

Abstract BACKGROUND Remote, smartphone‐based cognitive testing may improve access to cognitive assessments for Alzheimer's disease and related dementias. We evaluated the feasibility, reliability, and validity of unsupervised smartphone‐based cognitive tests in a registry‐based cohort. METHODS Adults without a record of cognitive impairment ( N = 1815; ages 18–92) were recruited from the University of California, San Francisco (UCSF) Brain Health Registry to complete three unsupervised smartphone cognitive testing sessions within 2 weeks. Reliability was assessed with correlations between sessions. Linear regression models tested associations of smartphone tasks with demographics, self‐ and informant‐rated cognitive concerns, and web‐based cognitive testing (Cogstate Brief Battery). RESULTS Adherence was high (82.2%) and usability favorable. Test–retest reliability was moderate to strong ( ρ ’s = 0.61–0.85, all p ’s < 0.001). Lower smartphone scores were associated with older age, lower education, cognitive concerns, and worse Cogstate performance. DISCUSSION Findings support the feasibility, reliability, and validity of remote digital assessments in adults without a record of cognitive impairment.